Seeking Alpha

Robert Fabian

View as an RSS Feed
View Robert Fabian's Comments BY TICKER:
Latest  |  Highest rated
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "You are correct that Adamis intends to run a POC"

    Yes that's why the product is NOT proven yet.

    "More importantly your conclusion that in one case 3M is jealously hoarding a device while in the other it cast it adrift is totally fallacious (as admittedly was my responsive theory of 3M incenting Radius)."

    Adamis bought the rights to 3Ms Taper DPI technology for $10m while Radius signed an agreement with 3M to develop their product with 3Ms patented TD technology. In one agreement 3M are giving up all rights to the technology while in the other they continue to have all rights to the technology. This speaks volumes on how 3M sees the potential of the Taper DPI technology. IMO.

    Also this "sure it's all about the Tape Supply Agreement" is a complete red herring. IMO.

    Adamis are going to need a lot of funds going forward and they will be going to the capital markets for them. Major dilution ahead. IMO.
    Apr 14 07:50 AM | Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "The protocol is easier enough that apparently it does not include a POC"

    Arghhhhhhhhhh. All companies run a POC trial in order to see if the product might be effective first. Companies don't just jump into Phase 3 trials blind. The paid research report even outlined this.

    "Why did 3M not agree to commercialize the APC-5000 product? Because it's pretty clear it isn't required."

    Sure who needs an experienced Sales and Marketing team like 3M have. Pretty clear a no product, no salesforce company like Adamis is ready for the bigtime and 3M will make lots of money off the tape. LOL.

    "You have ignored the dynamic I gave viz. 3M incenting Radius to progress much riskier Phase II development while they conserve their resources for their upcoming Phase III trial."

    I ignored it because i have no idea what you're on about. Radius signed an agreement with 3M for a transdermal patch for their product. They currently have an ongoing trial for an injection version of the same product. Looks like Radius are smart developing an injection-free version of their product with 3M as a collaborator. If you think 3M only signed up because they thought Radius needed their help then i disagree vehemently. 3M could have just collaborated on the development side yet they chose to collaborate on the commercial side also. It's obvious to me Adamis need lots of help on the commercial side of things.

    "Sorry, but I don't regard lightly 3M agreeing to let Adamis take 3M research and development staff whose personal development they spent years nurturing."

    So basically 3M are saying that their employees are free to leave and go work for Adamis. So tell me again how that is a good thing for 3M? Looks like another case of 3M washing there hands of anything associated with this product.

    In all seriousness you really need to get this notion that the upcoming trials for Adamis product will be less rigourous because it is completely ridiculous.
    Apr 11 06:04 AM | Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "Can you speak to the cash burn?"

    Cash burn is minimal at the moment because they only have 1 ongoing trial for an early stage drug. One of the paid for research notes said they will need nearly $18m to run the Phase 3 trial for APC-5000 alone. IMO there are many offerings coming down the road.
    Apr 10 08:51 AM | Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "Exactly, and that's why I wrote my post to you, after you'd written five.....balance, lol."

    My posts don't even come close to balancing out the hyperbolic nonsense that is being posted on SA and the rest of the web.

    Have a good day too!
    Apr 10 08:43 AM | Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "3M wants to encourage the more novel transdermal microneedle development requiring trials under very rigorous FDA protocols vs Adamis delivering branded generic via a proven device and subject to much less rigorous FDA protocols."

    The FDA has made the pathway to approval easier recently but if you think that implies the protocols for the APC-5000 Phase 3 trial will be less rigourous then you don't understand the bureaucratic FDA. Also this device is NOT proven so i've no idea where you got that from. The pre-clinical trials are exactly that, pre-clincial. They haven't even run a POC trial yet.

    "If you read the agreement between 3M and Adamis (which you obviously haven't) you will see that Adamis even has the right to hire the 3M people that developed the Taper device so there is a degree of collaboration that runs deeper than you suspect."

    Adamis bought the device off of 3M who spent years R&Ding it so of course they are made available for "hire". On the other hand 3M and Radius will work to develop and commercialize their product. Why did 3M not agree to commercialize the APC-5000 product?

    ""i can think of umpteen business reasons"

    This isn't twitter so no limit on what you can say. Please feel free to share everything.
    Apr 10 08:41 AM | Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "Current data indicates this platform technology has the potential to be compatible with a wide range of formulations; so add-in gross margin from supplying the tape delivery for all other drugs using the DPI technology."

    It will take Adamis another 3.5 years minimum to get to a stage where they may get approval for the APC-5000 product yet you are already talking about other drugs?

    "Some of us don't have the same viewpoint as you"

    That's what makes a market. I'm all for hearing both sides of a story.
    Apr 9 09:03 AM | Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "3M stands to profit from the tape that they manufacture...I would say that means Adamis is sharing part of the profits with 3M."

    I'm was referring to an agreement whereby Adamis would be obligated to share part of their profits with 3M. What you are talking about is something completely different.
    Apr 9 08:58 AM | Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "I think they think they have the potential to sell a lot of expensive tape, which is after all the business that they are in."

    3M are in the business of making money, be it tape or the host of other products they sell. They sold the Taper DPI technology to a company with limited experience in bringing products through the FDA process, limited manufacuting capabilities and more importantly, limited resources. It is obvious to me that there was no demand from other potential acquirers for this technology.

    Here's an example of a collaboration update where 3M signed an agreement to help develop and commercialize a product using 3M's drug delivery system.
    http://bit.ly/1g6UC3u
    Apr 9 08:47 AM | Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "On the other hand, 3M did have the right to accept $14 Million in stock in lieu of the $7,000,000 closing payment and did not exercise it."

    Yet another indicator of how 3M feels about the potential of this device. Thank you for highlighting this. :)
    Apr 8 03:04 PM | Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "Your observations in that respect are pointless as both Pfizer and 3M stand to make significant profit sharing from the sucess of Adamis and Mylan's sales."

    There is a massive difference between the Mylan/Pfizer agreement and the Adamis/3M outright sale of their device. Pfizer are entitled to regulatory milestones and profit sharing from Mylan sales, whilst 3M are entitled to nothing bar the monies they get from selling the tape to Adamis.
    Apr 8 02:21 PM | 1 Like Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "Robert, let's see what the stock does when Adamis proves they can deliver 25% less drug with the same efficacy as Advair."

    This CUP tests were done on the lower dose Advair and it was not 25% overall. You can cut and paste all you want from these tests but they mean nothing when you take into account what Adamis paid for the device. You will actually see in one of your links that they had planned "Future Work" to test it themselves on humans back it 2011 but looks like they never did and has been up for sale since. What does that tell you?

    "we'll be discussing multi-bags."

    More like Bagholding. :)
    Apr 8 02:14 PM | 1 Like Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    "Robert, obviously you didn't hit any of the above links within the article that clearly point to 3M's research that indicate superiority in head to head testing against Glaxo's Advair."

    "Head to Head testing" is wording they use in clincial trials not pre-clinical trials. The 3M trials were NOT done on humans. If those links you posted were concrete evidence of a "superior" product then 3M wouldn't have sold the device for a measly $10m.

    "I'll be stunned if they don't have a partner by then to foot any and all expenses going forward."

    I'd be stunned if they ever sign a partner. I see massive dilution going forward. JMHO.
    Apr 8 01:30 PM | 1 Like Like |Link to Comment
  • Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq [View article]
    You also seem to be caught up in the hype of the $10m device that they bought from 3M. You say "Not only did 3M build a rival product, they built a far superior product." You're the second poster on SA that has determined the product is far superior to a $6B product on the market based on "in vitro" testing. 3M has clearly seen the results and valued it accordingly i.e. $10m. What sticks out most about the device purchase is the fact that 3M sold it outright with no future milestones or profit sharing. The $10m would hardly cover a fraction of 3M's R&D expenses on it. They basically just gave it away.

    By the way Adamis has 1 ongoing trial (APC-100), which is early stage. There are NO other ongoing trials currently. They have a timetable for the APC-5000 and PFS products and the rest are in waiting. Looks like they have changed all focus since they bought the device. Doesn't say much for their pipeline. IMO.

    The road ahead is long with many offerings along the way. They will need up to $20m to bring the APC-5000 product through clinical trials alone.
    Apr 8 12:55 PM | 3 Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Two Companies For The Price Of One [View article]
    "You don't believe Adamis could capture $150 million out of an $8 billion market worldwide (and probably much higher in two years)?"

    In order for me to believe this arbitrary figure of $150m, thrown out by the book-runner to the offering, then i would have to assume that Adamis are capable of 1) Manufacturing this device 2) Designing clincial trials 3) Getting the product through the FDA approval process 4) Putting sales team in place 5) Marketing this product to compete with Big Pharma

    At the moment, no i don't believe they can capture any sales.

    "And that is just one product in the pipeline!"

    Besides the EpiPen product i really don't see anything worth talking about. Maybe in another few years they may have some decent data to work on.
    Apr 8 08:49 AM | Likes Like |Link to Comment
  • Adamis Pharmaceuticals: Two Companies For The Price Of One [View article]
    "As I mentioned in my comment, it is the manufacturing of the most important component, the tape with the medication, that 3M will maintain control over."

    This is what you actually said: "They want to make money manufacturing this device, supplying the tape required". Obviously you didn't know that Adamis were planning on manufacturing the device themselves until you read the research report, and now you are conveniently twisting your statement. Also the drug delivery tape is supplied WITHOUT the medication in case you thought otherwise.

    "As for competition, no one else has 3M's Taper DPI which 3M itself has tested vigorously and shown to be better than Advair Diskus on many fronts."

    The DISKUS is not a Taper DPI device so it doesn't matter whether the competition are using tape or not. And i don't know how you can say the 3M device has been "tested vigorously" when NO HUMAN trials have been performed on it?

    James you clearly have gotten caught up in the hype around the $10m purchase of the 3M device but i suggest you do a lot more research if you intend on submitting a follow-up article. Good luck.
    Apr 8 08:33 AM | Likes Like |Link to Comment
COMMENTS STATS
47 Comments
19 Likes